121123-17-9

Basic information

• Product Name: Cefprozil hydrate
• Synonyms: ceftibutin;Cefprozil hydrate (Cefzil);Cefprozil for Suspension;(6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propen-1-yl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, hydrate (1:1);(6R,7R)-7-[(R)-2-Amino-2-(p-hydroxyphenyl)acetamido]-8-oxo-3-propenyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate;Cefprozil (200 mg);CEFZIL;CEFPROZIL HYDRATE
• CAS NO: 121123-17-9
• Molecular Formula: C18H21N3O6S
• Molecular Weight: 407.44
• Product Categories: Pharmaceutical intermediate;DBI
• Mol File: 121123-17-9.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 803.1 °C at 760 mmHg
• Flash Point: 439.5 °C
• Appearance: solid
• Density: 1.534g/cm3
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.718
• Storage Temp.: Store at 0-5°C
• Solubility: Slightly soluble in water and in methanol, practically insoluble in acetone.
• CAS DataBase Reference: Cefprozil hydrate(CAS DataBase Reference)
• NIST Chemistry Reference: Cefprozil hydrate(121123-17-9)
• EPA Substance Registry System: Cefprozil hydrate(121123-17-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-42/43
• Safety Statements: 22-26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 121123-17-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Cefprozil hydrate is used as an antibacterial agent for treating a wide range of bacterial infections. Its effectiveness lies in its ability to inhibit bacterial cell wall synthesis, leading to the destruction of the bacterial cell. This makes it a valuable component in the development of antibiotics to combat various infections.
Used in Antidiabetic Applications:
Cefprozil hydrate is also utilized in the field of antidiabetic medications. While its primary function is as an antibiotic, it has been found to have potential benefits in managing and treating diabetes. The exact mechanism of action in this context may vary, but it is believed to contribute to the overall regulation of blood sugar levels and the management of diabetes-related complications.

InChI:InChI=1/C18H19N3O5S/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26)/b3-2-

Upstream product

• 886219-90-5 (6R,7R)-7-[2-amino-2-(4-hydroxyphenyl)acetamido]-3-[(Z)-propenyl]-3-cephem-4-carboxylic acid dimethylformamide solvate 

Relevant articles and documents

A NOVEL PROCESS FOR PREPARATION OF CEFPROZIL INTERMEDIATE

The present invention relates to a process for preparing a key intermediate of cefprozil and use of this intermediate in the preparation of cefprozil thereby avoiding impurity-causing self-acylation. [R-(Z)]-[4-hydroxy-α-[(3-methoxy-l-methyl-3-oxo-1-propenyl)amino]] benzeneacetic acid, mono potassium salt is reacted with ethyl chloroformate to obtain mixed anhydride which is then silylated with N,O-bis(trimethylsilyl)acetamide. The silylated compound obtained is reacted with [7-trimethylsilylamino-3-(Z/E-propen-1-yl)-3-cephem-4-carboxylic acid]trimethylsilyl ester and deprotected with aqueous hydrochloric acid to give cefprozil.

Process for preparation of 7-[alpha-amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid

A process for preparation of 7-[D-α-amino-α-(4-hydroxyphenyl)acetamido]-3-(1-propen-1-yl)-3-cephem-4-carboxylic acid viz. Cefprozil of formula (I) igh purity, substantially free of impurities, which comprises preparation of mixed acid anhydride by selecting the sequence and temperature of addition of the reagents and its subsequent condensation with a protected 7-APCA; followed by hydrolysis, isolation and purification to give Cefprozil of formula (I) in the form of a monohydrate.